Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) closed the day trading at $22.68 down -1.48% from the previous closing price of $23.02. In other words, the price has decreased by -$1.48 from its previous closing price. On the day, 1.44 million shares were traded. CNTA stock price reached its highest trading level at $23.31 during the session, while it also had its lowest trading level at $22.66.
Ratios:
For a better understanding of CNTA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.57 and its Current Ratio is at 10.57. In the meantime, Its Debt-to-Equity ratio is 0.39 whereas as Long-Term Debt/Eq ratio is at 0.39.
On October 28, 2025, Stephens started tracking the stock assigning a Overweight rating and target price of $35.
On September 03, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $31.Wells Fargo initiated its Overweight rating on September 03, 2025, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 02 ’26 when Saurabh Saha bought 2,500,000 shares for $24.30 per share.
Accardi Mario Alberto sold 10,000 shares of CNTA for $288,289 on Dec 09 ’25. The President, Orexin Program now owns 178,801 shares after completing the transaction at $28.83 per share. On Dec 09 ’25, another insider, Accardi Mario Alberto, who serves as the Officer of the company, bought 10,000 shares for $29.30 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CNTA now has a Market Capitalization of 3312997888 and an Enterprise Value of 2921321984. For the stock, the TTM Price-to-Sale (P/S) ratio is 202.43 while its Price-to-Book (P/B) ratio in mrq is 10.11. Its current Enterprise Value per Revenue stands at 194.755 whereas that against EBITDA is -13.684.
Stock Price History:
The Beta on a monthly basis for CNTA is 1.57, which has changed by 0.42981362 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, CNTA has reached a high of $30.58, while it has fallen to a 52-week low of $9.60. The 50-Day Moving Average of the stock is -12.88%, while the 200-Day Moving Average is calculated to be 21.94%.
Shares Statistics:
Over the past 3-months, CNTA traded about 1.56M shares per day on average, while over the past 10 days, CNTA traded about 1106490 shares per day. A total of 134.42M shares are outstanding, with a floating share count of 88.33M. Insiders hold about 34.29% of the company’s shares, while institutions hold 59.86% stake in the company. Shares short for CNTA as of 1765756800 were 5662349 with a Short Ratio of 3.63, compared to 1763078400 on 5921306. Therefore, it implies a Short% of Shares Outstanding of 5662349 and a Short% of Float of 4.44.
Earnings Estimates
The stock of Centessa Pharmaceuticals plc ADR (CNTA) is currently drawing attention from 9.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.38 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$1.05 and -$1.42 for the fiscal current year, implying an average EPS of -$1.34. EPS for the following year is -$1.65, with 10.0 analysts recommending between -$1.24 and -$2.02.
